
Blackstone Life Sciences Advances AML Treatment With Bleximenib Funding
BXLS and Johnson & Johnson Collaborate to Fund Bleximenib Clinical Trials for AML Why is the development of new treatments for acute myeloid leukemia (AML) so critical? Despite being the most common acute leukemia in adults, AML remains an extremely…












